Geron to Discontinue Phase 3 Imetelstat Trial in Myelofibrosis
Geron disclosed in an SEC filing that it will discontinue the Phase 3 IMpactMF trial of imetelstat in myelofibrosis.
Story updates
08:53:23 PM UTC
SquawkNews
Geron will discontinue its Phase 3 IMpactMF trial after an independent committee concluded it was unlikely to meet its overall survival endpoint.Key Highlights:Original SEC Filing: GERON CORP [ GERN ] - 8-K - Oct. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifyin…